What long-term studies exist for Cosentyx (secukinumab)?
Yes—Cosentyx’s long-term evidence includes multi-year extension studies that track patients after initial trial periods, and they are used by regulators and clinicians to understand durability of response and longer-term safety.
Have the long-term results shown sustained effectiveness?
Across long-term follow-up, the key question is whether responses seen early (such as symptom and inflammatory marker improvements) persist over years. Long-term extensions are designed to evaluate whether patients maintain those improvements, how many remain on treatment, and whether response gradually declines or stabilizes.
What long-term safety data is reported?
Long-term studies typically track:
- Rates and types of adverse events over extended exposure
- Serious infections and other significant risks
- Injection-related reactions
- Ongoing monitoring for risks relevant to immune modulation
How do you interpret “long term” in Cosentyx trials?
“Long term” usually means patients followed for years through extension phases beyond the core trial. The exact duration and patient populations vary by indication (for example, plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis), and results are not identical across conditions.
Which data would you want reviewed specifically?
If you tell me the indication (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, etc.) and what you mean by “long term” (e.g., 3 years, 5 years, 10 years), I can narrow to the most relevant extension-study endpoints you should look for (durability of response and long-term adverse event patterns).
Important limitation
I don’t have access here to a live database to “review” every publication or topline table. If you share a specific study name, publication link, or trial identifier (e.g., a years-long extension report), I can summarize what it shows and how the long-term outcomes compare with earlier results.
Quick question so I can target the right data
Which condition are you asking about, and do you want effectiveness durability, long-term safety, or both?